By blocking inhibitory PD-1/CTLA-4 pathways, ICIs activate inhibited T cells thereby enhancing the immune system’s ability to attack tumor cells; however, this activation can cause T cell overactivation, resulting in the loss of immune tolerance, particularly in mucosal tissues, which is a key driver of irColitis (75). The gene discussed is PDCD1; the disease is neoplasm.